Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.19), $0.05 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.43 million versus the consensus estimate of $80.93 million.

GUIDANCE:

Iovance Biotherapeutics sees Q2 2026 revenue of $86-88 million, versus the consensus of $84.36 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.